Literature DB >> 19896096

Molecular pathology of pancreatic cancer: implications for molecular targeting therapy.

Toru Furukawa1.   

Abstract

Pancreatic cancer develops through ductal dysplastic lesions or pancreatic intraepithelial neoplasia (PanIN). The origin of pancreatic cancer remains controversial. Some of the molecular origins of pancreatic cancer have been described. For example, KRAS, SHH, CDKN2A, TP53, SMAD4, and DUSP6 are crucial molecules in the development and progression of pancreatic cancer. Understanding the mechanisms of carcinogenesis could help researchers find the Achilles' heel of pancreatic cancer. Molecular targeting is a promising strategy for curing this devastating disease.

Entities:  

Mesh:

Year:  2009        PMID: 19896096     DOI: 10.1016/j.cgh.2009.07.035

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.

Authors:  Yuanhong Xu; Zhe Liu; Kejian Guo
Journal:  Pathol Oncol Res       Date:  2011-11-23       Impact factor: 3.201

2.  KNTC1 as a putative tumor oncogene in pancreatic cancer.

Authors:  Ling Liu; Hongwei Chen; Xinan Chen; Chenjie Yao; Weimin Shen; Changku Jia
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-19       Impact factor: 4.322

3.  DUSP6 regulates drug sensitivity by modulating DNA damage response.

Authors:  T V Bagnyukova; D Restifo; N Beeharry; L Gabitova; T Li; I G Serebriiskii; E A Golemis; I Astsaturov
Journal:  Br J Cancer       Date:  2013-07-09       Impact factor: 7.640

4.  Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.

Authors:  James M Lindberg; Timothy E Newhook; Sara J Adair; Dustin M Walters; Alison J Kim; Edward B Stelow; J Thomas Parsons; Todd W Bauer
Journal:  Neoplasia       Date:  2014-07       Impact factor: 5.715

Review 5.  TGF-β - an excellent servant but a bad master.

Authors:  Lenka Kubiczkova; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Transl Med       Date:  2012-09-03       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.